Overview
Patients with chronic lymphocytic leukemia (CLL) who have been treated with both covalent BTK inhibitors (cBTKi) and B-cell lymphoma 2 inhibitors (BCL2i) often face limited treatment options if their disease returns or stops responding to these therapies. This research used the Flatiron Health Research Database to evaluate real-world treatment patterns and outcomes for 264 such patients, specifically comparing those who had received both treatments ("double exposed") to those whose cancer was resistant to both ("double refractory").
Researchers found that while many patients were retreated with the same classes of drugs, initial responses to treatment were similar across groups, those with double refractory disease had significantly poorer outcomes. Specifically, median overall survival for the double refractory group was only 14.7 months, compared to 38.2 months for patients who had been exposed to both drugs but were not resistant. The study also observed that the durability of response and survival time became shorter with each subsequent line of therapy. These findings suggest that while treatments may initially work, their benefit tends to be less durable in patients with resistant disease.
Why this matters
These findings highlight a major unmet medical need for more effective and durable treatment options for CLL patients who have failed the current standard-of-care therapies. The research underscores that although existing therapies can still induce responses, retreating with existing drug classes provides limited long term benefit for those with resistant disease, emphasizing the urgent need for novel therapies.
Importantly, the study distinguishes between patients who have been exposed to these therapies and those whose disease is truly resistant, suggesting that these groups may require different treatment approaches and should be considered separately in future research and clinical trials.
By using high-quality real-world data to identify these gaps in care, this study helps clinicians better understand patient prognosis and treatment sequencing challenges and supports efforts for the development of new treatment strategies to improve long-term survival and quality of life.